What it is: A weekly injectable GLP-1 hormone analog approved for both type 2 diabetes (Ozempic) and chronic weight management (Wegovy).
Research suggests: The STEP clinical trials showed an average of nearly 15% body weight reduction over 68 weeks - among the largest results ever demonstrated in a pharmaceutical weight loss trial.
Best for: Metabolic health and weight management researchers
Key thing to know: Among the most clinically studied compounds on this platform, with multiple large-scale independent RCTs and regulatory approval for two distinct indications.
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist, a synthetic version of glucagon-like peptide-1. GLP-1 is released by gut cells in response to food and helps signal fullness, regulate insulin, and slow digestion. Semaglutide was originally developed for type 2 diabetes and is approved under the brand names Ozempic (diabetes) and Wegovy (chronic weight management).
Researchers have studied semaglutide extensively for weight loss, blood sugar regulation, cardiovascular risk reduction, and broader metabolic health optimization. It represents one of the most well-studied compounds in the GLP-1 class, with multiple large-scale randomized controlled trials establishing its efficacy and safety profile across diverse populations.
How it works.
In research, the proposed mechanism has several parts.
GLP-1 mimic: GLP-1 is a natural hormone released by your gut after you eat. It signals your pancreas to produce insulin (to manage rising blood sugar), slows the rate at which your stomach empties food into the intestine (so you feel full longer), and reduces appetite signals in areas of the brain that regulate hunger, particularly the hypothalamus.
How it is engineered: Semaglutide mimics this hormone but is engineered to last much longer in the body, approximately seven days per subcutaneous injection compared to the minutes that natural GLP-1 remains active. This sustained action produces continuous appetite suppression, prolonged satiety after meals, and stable blood sugar regulation throughout the week.
In plain terms: Think of it as amplifying your body's natural after-meal fullness signal and keeping it active for days rather than hours. Studies indicate that this mechanism also acts on reward pathways involved in food-seeking behavior, which may explain why research subjects report reduced cravings and changed food preferences beyond simple caloric restriction.
What the research shows.
The research evidence breaks down as follows.
A strong evidence base: Semaglutide has one of the strongest evidence profiles on this platform. The SUSTAIN clinical trial series, multiple large Phase 3 randomized controlled trials, established its efficacy and safety in type 2 diabetes across thousands of participants versus placebo and active comparators. These trials consistently showed meaningful reductions in HbA1c and body weight.
The STEP trials: The STEP trial series examined semaglutide for chronic weight management in people with obesity (without type 2 diabetes). STEP 1 showed an average 14.9% body-weight reduction over 68 weeks, among the largest weight-loss results ever demonstrated in a pharmaceutical trial. Subsequent STEP trials confirmed these findings across populations, including those with cardiovascular risk factors.
The SELECT trial: The SELECT trial further demonstrated a 20% reduction in major cardiovascular events in people with obesity and established cardiovascular disease.
Evidence level: This is Strong evidence, multiple independent, large-scale human RCTs with consistent, replicated findings, extensive safety monitoring, and regulatory approval. The evidence base is extensive and well-established in the peer-reviewed literature.
Biomarkers to review first.
Research protocols for semaglutide typically reference the following biomarkers as baseline context. Testing these before exploring this compound gives you and your healthcare provider the most relevant starting information.
See the full lab testing guide →What it's commonly researched with.
In research literature, semaglutide appears in comparison studies with related GLP-1 compounds and in combination research examining metabolic and longevity outcomes. The entries below represent what appears in the research literature, not combinations to pursue without medical supervision.
Goals & biomarkers connected to this peptide.
Go deeper
How semaglutide, a single GLP-1 agonist, laid the foundation for the modern metabolic peptide class.
Read Research →